- Home
- AEHL vs APRE Comparison
AEHL vs APRE Comparison
Compare AEHL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEHL
- APRE
- Stock Information
- Founded
- AEHL 1993
- APRE 2006
- Country
- AEHL China
- APRE United States
- Employees
- AEHL N/A
- APRE N/A
- Industry
- AEHL Building Materials
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEHL Industrials
- APRE Health Care
- Exchange
- AEHL Nasdaq
- APRE Nasdaq
- Market Cap
- AEHL 8.5M
- APRE 10.0M
- IPO Year
- AEHL 2007
- APRE 2019
- Fundamental
- Price
- AEHL $2.72
- APRE $1.71
- Analyst Decision
- AEHL
- APRE Strong Buy
- Analyst Count
- AEHL 0
- APRE 2
- Target Price
- AEHL N/A
- APRE $15.50
- AVG Volume (30 Days)
- AEHL 124.1K
- APRE 50.9K
- Earning Date
- AEHL 05-01-2025
- APRE 08-11-2025
- Dividend Yield
- AEHL N/A
- APRE N/A
- EPS Growth
- AEHL N/A
- APRE N/A
- EPS
- AEHL N/A
- APRE N/A
- Revenue
- AEHL $98,773,000.00
- APRE $1,284,475.00
- Revenue This Year
- AEHL N/A
- APRE N/A
- Revenue Next Year
- AEHL N/A
- APRE N/A
- P/E Ratio
- AEHL N/A
- APRE N/A
- Revenue Growth
- AEHL 36.99
- APRE 33.27
- 52 Week Low
- AEHL $1.79
- APRE $1.41
- 52 Week High
- AEHL $256.40
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- AEHL 53.14
- APRE 52.34
- Support Level
- AEHL $2.33
- APRE $1.48
- Resistance Level
- AEHL $2.75
- APRE $1.91
- Average True Range (ATR)
- AEHL 0.25
- APRE 0.16
- MACD
- AEHL 0.05
- APRE -0.00
- Stochastic Oscillator
- AEHL 69.70
- APRE 63.14
About AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.